Matica Biotechnology

Matica Biotechnology

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Matica Biotechnology, founded in 2015 and headquartered in College Station, Texas, is a specialized viral vector and gene therapy CDMO. It offers a full suite of services including cell line development, process and assay development, and GMP production, supported by its proprietary MatiMax™ platform and single-use technologies. The company has a global footprint with five sites and a track record of over 300 vector projects, positioning it as a key manufacturing partner for biotech firms advancing cell and gene therapies.

Cell TherapyGene Therapy

Technology Platform

MatiMax™ proprietary cell line platform for viral vector production, combined with advanced single-use bioprocessing equipment and in-line analytics.

Opportunities

The company is positioned to capitalize on the massive and growing global demand for viral vector manufacturing capacity, driven by the rapid expansion of the cell and gene therapy pipeline.
Its proprietary MatiMax™ platform and focus on speed-to-clinic offer a competitive edge in attracting clients seeking efficient development partners.

Risk Factors

Key risks include intense competition from both large, diversified CDMOs and other niche players, reliance on the clinical and regulatory success of client therapies, and operational risks associated with the complex scale-up of viral vector manufacturing under stringent GMP standards.

Competitive Landscape

Matica competes in the specialized viral vector CDMO space against large, established players like Lonza and Catalent, as well as other focused competitors such as Oxford Biomedica, Genezen, and Vigene Biosciences. Differentiation is achieved through proprietary technology (MatiMax™), a purpose-built facility, and a client-centric service model emphasizing speed and quality.